Specifications TableSubjectCardiology and Cardiovascular MedicineSpecific subject areaMolecular cardiology (molecular mechanisms of dilated cardiomyopathy)Type of dataTable\
Graph\
FigureHow data were acquiredChemiluminescence was measured photometrically on an Infinite M200 PRO system (Tecan).Data formatAnalysedParameters for data collectionACTC1 gene mutations mentioned in [Table 1](#tbl1){ref-type="table"} were inducted by site directed mutagenesis and used to perform the luciferase activity. Data from all the mutant genes is compared with the wild-type ACTC1 to determine the functional impact of respective mutations.Description of data collectionC2C12 cells were transfected with either wild-type or one of the mutant ACTC1 together with Renilla-luciferase and Firefly-luciferase. Media was changed post 6 h transfections and cells were further incubated for 48 h. Cells were then washed twice with PBS, lysed with the active lysis buffer and the assay was performed using dual luciferase reporter assay kit (Promega), according to the manufacturer\'s instructions. Bioluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). All the experiments were performed in hexaplicate and repeated two times.Data source locationInstitution: University Medical Centre Kiel\
City/Town/Region: Kiel\
Country: GermanyData accessibilityWith the articleRelated research articleRangrez et al., A cardiac α-actin (ACTC1) p. Gly247Asp mutation inhibits SRF-signaling in vitro in neonatal rat cardiomyocytes. Biochem Biophys Res Commun. [https://doi.org/10.1016/j.bbrc.2019.08.081](10.1016/j.bbrc.2019.08.081){#intref0010}.**Value of the Data**•Present data is a preliminary evidence of the differential functional impact ACTC1 genetic mutations on SRF-signaling•These data provide a basis molecular cardiologists working on ACTC1 for further evaluation of these ACTC1 mutations for genotype-phenotype correlations•Functional differences obtained here highlight the fact that different localizations of known or yet to be identified ACTC1 mutations affect the tertiary structure thereby affecting protein-protein interactions, which needs to be experimentally validated.

1. Data description {#sec1}
===================

Cardiac α-actin is a fundamental structural protein necessary for the maintenance of myofibrillar integrity of the heart by forming thin filaments with tropomyosin and three troponins (C, I, and T). Several isolated ACTC1 mutations have been reported till date ([Fig. 1](#fig1){ref-type="fig"}) causing atrial-septal-defect, dilated and hypertrophic cardiomyopathy ([Table 1](#tbl1){ref-type="table"}). Majority of these ACTC1 mutants though have not been investigated for their functional consequence. Based on our findings from G247D mutation on SRF-signaling \[[@bib1]\], we aimed here at deciphering the functional impact of ACTC1 genetic mutations on SRF-signaling using SM22-response element driven Firefly luciferase activity assay in C2C12 cells. The data is shown in [Fig. 2](#fig2){ref-type="fig"} and the respective raw and analysed data is provided in a separate excel file.Fig. 1Known human *ACTC1* gene mutations are depicted pictorially. Mutations are described as the nuclic acid change in the coding DNA and the resulting amino acid change in the protein in brackets. ATG = start codon, c = coding DNA, p = protein, TAA = stop codon, UTR = untranslated region.Fig. 1Table 1**Location and associated cardiac phenotypes of human ACTC1 gene mutations.** Listed are the description of the mutation on DNA and protein level as descripted in this article (and corresponding description according to the reference sequence from the NCBI database), the exon and the protein domain in which the mutation is located and reported cardiac phenotypes. ASD = atrial septal defect, ASD II = ostium secundum atrial septal defect, HCM = hypertrophic cardiomyopathy, LVNCC = left ventricular non compaction cardiomyopathy, MR = mitral regurgitation, RCM = restrictive cardiomyopathy.Table 1coding DNA:\
nucleotide acid change\
(NM_005159.5)exonprotein:\
amino acid change\
(NP_001091.1)protein domainclinical cardiac phenotypereferencesc.301G\>A3p.E99K\
(p.Glu101Lys)subdomain 1ASD, LVNCC, apical HCM, RCM, MROlson et al. 2000 \[[@bib2]\],\
Arad et al. 2005 \[[@bib3]\],\
Monserrat et al. 2007 \[[@bib4]\]c.373A\>G3p.M123V\
(p.Met125Val)subdomain 1, hydrophobic coreASD-IIMatsson et al. 2008 \[[@bib5]\]c.740G\>A5p.G245D\
(p.Gly247Asp)subdomain 3ASD-II, atrial arrhythmias, late onset DCM,Frank et al. 2019 \[[@bib6]\],\
Rangrez et al. 2019 \[[@bib1]\]c.941G\>A6p.R312H\
(p.Arg314His)subdomain 3, tropomyosin binding siteDCMOlson et al.1998 \[[@bib7]\]c.1088A\>G7p.E361G\
(p.Glu363Gly)subdomain 3, Actinin binding siteDCMOlson et al.1998 \[[@bib7]\]Fig. 2Relative luciferase activity in C2C12 cells deduced from SM22 reporter-driven firefly luciferase for the human wild-type and ACTC1-mutant proteins. (n = 6/group).Fig. 2

2. Experimental design, materials, and methods {#sec2}
==============================================

2.1. Cloning of wild-type and mutant ACTC1 {#sec2.1}
------------------------------------------

Wild-type human ACTC1 gene was cloned into PDONR221 using Gateway technology (BP clonase II reaction, Life technologies) and subsequently recombined into mammalian expression vector pDEST47 (LR clonase II reaction, Life technologies). Site-directed mutagenesis for ACTC1 single nucleotide variants was performed using QuikChange XL Kit (Stratagene) according to manufacturer\'s instructions. All the constructs were verified by Sangers sequencing to confirm the ACTC1 genotypes.

2.2. Luciferase reporter gene assay {#sec2.2}
-----------------------------------

C2C12 cells at the confluency of approximately 50% in 12xwell plates were transfected with either wild-type or one of the mutant ACTC1 plasmids together with SM22-promoter driven Firefly-luciferase construct as well as Renilla luciferase under the control of a thymidine kinase promoter (pRLTK) to normalize for transfection efficiency. Media was changed post 6 h transfections and cells were further incubated for 48 h. Cells were then washed twice with PBS, lysed with 150 μl of the active lysis buffer by shaking the plates on a horizontal plate shaker for 20 min. Luciferase assay was performed with 20 μl of the lysates using dual luciferase reporter assay kit according to the manufacturer\'s instructions (Promega) in 96-well luminometry plates. Bioluminescence was measured photometrically on an Infinite M200 PRO system (Tecan). All the experiments were performed in hexaplicate and repeated two times.
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